AbbVie Inc (ABBV)vsRoyalty Pharma Plc (RPRX)
ABBV
AbbVie Inc
$209.40
+1.78%
HEALTHCARE · Cap: $370.38B
RPRX
Royalty Pharma Plc
$46.35
-1.26%
HEALTHCARE · Cap: $26.81B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2472% more annual revenue ($61.16B vs $2.38B). RPRX leads profitability with a 32.4% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.50. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1199.0%
Fair Value
$16.12
Current Price
$209.40
$193.28 premium
Margin of Safety
-17.3%
Fair Value
$37.74
Current Price
$46.35
$8.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 88.3x leaves little room for execution misses.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?